Firstly, this is purely to remove the stock from mine and everybody else's radar as Simply is showing this as an undervalued company which is essentially dead in the water and not currently tradeable on the exchange.
The following is AI, not my own words, which has a far more explanatory way of putting this.
The Situation with TRACON Pharmaceuticals
• Clinical trial failure: In mid‑2024, TRACON’s pivotal trial of envafolimab (a PD‑L1 inhibitor for rare sarcomas) failed to meet its primary endpoint. The response rate was only 5%, well below the 11% target.
• Decision to wind down: Following this failure, TRACON announced it would wind down operations, abandoning plans to seek FDA approval. Envafolimab had already been approved in China, but the U.S. trial results killed its prospects.
• Delisting risk: MarketBeat notes the company is potentially delisted and may not be actively trading on NASDAQ anymore.
Current Value
• Stock price: As of late 2025, TRACON’s shares trade in the $0.02–$0.08 range, having collapsed from highs of $14.75 within the past year.
• Market cap: Around $110,000 USD, which is minuscule for a biotech and signals that the market sees almost no future value.
• Liquidity: Trading volume is very low, meaning shares are highly illiquid and speculative.
What This Means
• Practically worthless: The company has no viable pipeline left, no revenue prospects, and is winding down. Shares are essentially a shell.
• Speculative only: Any remaining trading activity is speculative, not based on fundamentals.
How well do narratives help inform your perspective?
Disclaimer
The user Investor_Ninja has a position in OTCPK:TCON. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.